drugset
Drugs / BI 187004
last change Aug 2021 re-read 9 days ago

BI 187004

Small molecule targets HSD11B1 via inhibition

Developed for
type 2 diabetes mellitus
Investigated by
Boehringer Ingelheim

Trials 7

today NCT02305901 · Ph 1 NCT02254148 · Ph 1 NCT02150824 · Ph 2 NCT02161432 · Ph 1 NCT02109679 · Ph 1 NCT01874483 · Ph 1 NCT01587417 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT02305901 Dec 2014 → Mar 2015 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02254148 Oct → Dec 2014 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02161432 Jun → Sep 2014 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02109679 May → Jul 2014 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01874483 Jun → Dec 2013 type 2 diabetes mellitus Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01587417 Apr → Oct 2012 — Boehringer Ingelheim Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02150824 Jul 2014 → Jul 2015 type 2 diabetes mellitus Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as BI 187004 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01874483 ↗
6

NCT02150824 ↗

NCT02305901 ↗

NCT02109679 ↗

NCT02161432 ↗

NCT02254148 ↗

NCT01587417 ↗
Action Inhibit “BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1” PMID 34391480 ↗ Aug 2021
1

“11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL3669417 ↗
Modality Small molecule — CHEMBL3669417 ↗
Route Oral “single oral doses of BI 187004” PMID 34391480 ↗ Aug 2021
Target HSD11B1 “11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL3669417 ↗